IL17A and autoimmune polyendocrine syndrome type 1: The description of mild or moderate oral candidiasis in up to 21% of patients treated with therapeutic Abs blocking IL-17A/F signaling (Reich et al., 2021) was predicted by studies of APS-1 patients (Kisand et al., 2021; Philippot et al., 2021; Puel and Casanova, 2021; Table 1).